Budesonide in the treatment of inflammatory bowel disease

References

• Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut49(6), 777–782 (2001).
   PubMed Web of Science ®Google Scholar
• Sawczenko A, Sandhu BK, Logan RF et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet357(9262), 1093–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology95(6), 1523–1527 (1988).
   PubMed Web of Science ®Google Scholar
• Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.18(2), 165–173 (1994).
   PubMed Web of Science ®Google Scholar
• Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm. Bowel Dis.14(6), 839–849 (2008).
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet369(9573), 1641–1657 (2007).
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology121(2), 255–260 (2001).
   PubMed Web of Science ®Google Scholar
• Löfberg R, Danielsson A, Salde L. Oral budesonide in active Crohn’s disease. Aliment Pharmacol. Ther.7(6), 611–616 (1993).
   PubMed Web of Science ®Google Scholar
• Dahlberg E, Thalén A, Brattsand R et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 α, 17 α-acetal-substituted glucocorticoids. Mol. Pharmacol.25(1), 70–78 (1984).
   PubMed Web of Science ®Google Scholar
• Hofer KN. Oral budesonide in the management of Crohn’s disease. Ann. Pharmacother.37(10), 1457–1464 (2003).
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv. Drug Deliv. Rev.57(2), 303–316 (2005).
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Larsson P, Wollmer P. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. Eur. J. Gastroenterol. Hepatol.14(12), 1357–1362 (2002).
   PubMed Web of Science ®Google Scholar
• Brunner M, Ziegler S, Di Stefano AF et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br. J. Clin. Pharmacol.61(1), 31–38 (2006).
   PubMed Web of Science ®Google Scholar
• Fiorino G, Fries W, De La Rue SA, Malesci AC, Repici A, Danese S. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr. Med. Chem.17(17), 1851–1857 (2010).
   PubMed Web of Science ®Google Scholar
• Crcarevska MS, Dodov MG, Petrusevska G, Gjorgoski I, Goracinova K. Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis. J. Drug Target.17(10), 788–802 (2009).
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Emami J, Ahmadi F et al. Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis. J. Drug Target.19(2), 140–153 (2010).
   PubMedGoogle Scholar
• Varshosaz J, Emami J, Fassihi A et al. Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats. Int. J. Colorectal Dis.25(10), 1159–1165 (2010).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol. Allergy Clin. North Am.25(3), 451–468 (2005).
   PubMed Web of Science ®Google Scholar
• Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can. J. Gastroenterol.4, 407–414 (1990).
   Google Scholar
• Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin. Pharmacokinet.43(12), 803–821 (2004).
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet.42(1), 59–98 (2003).
   PubMed Web of Science ®Google Scholar
• Jönsson G, Aström A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos.23(1), 137–142 (1995).
   PubMed Web of Science ®Google Scholar
• Lundin P, Naber T, Nilsson M, Edsbäcker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn’s disease. Aliment Pharmacol. Ther.15(1), 45–51 (2001).
   PubMed Web of Science ®Google Scholar
• Lundin PDP, Edsbäcker S, Bergstrand M et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn’s disease. Aliment Pharmacol. Ther.17(1), 85–92 (2003).
   PubMed Web of Science ®Google Scholar
• Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. (3), CD000296 (2008).
   PubMedGoogle Scholar
• Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L. Budesonide in the treatment of Crohn’s disease: a meta-analysis. Aliment Pharmacol. Ther.14(11), 1419–1428 (2000).
   PubMed Web of Science ®Google Scholar
• Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol. Ther.16(8), 1509–1517 (2002).
   PubMed Web of Science ®Google Scholar
• Levine A, Kori M, Dinari G et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn’s disease: a randomized placebo-controlled trial. Inflamm. Bowel Dis.15(7), 1055–1061 (2009).
   PubMed Web of Science ®Google Scholar
• Tromm A, Bunganic I, Tomsova E et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology140(2), 425–434; e421; quiz e413–e424 (2011).
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Christidou A, Sfakianakis M et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm. Bowel Dis.15(3), 375–382 (2009).
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J. Crohn’s Colitis4(1), 28–62 (2010).
   Google Scholar
• Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. (1), CD002913 (2009).
   PubMedGoogle Scholar
• Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst. Rev. (4), CD006873 (2009).
   Google Scholar
• Greenberg GR, Feagan BG, Martin F et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology110(1), 45–51 (1996).
   PubMed Web of Science ®Google Scholar
• Ferguson A, Campieri M, Doe W, Persson T, Nygård G. Oral budesonide as maintenance therapy in Crohn’s disease – results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol. Ther.12(2), 175–183 (1998).
   PubMed Web of Science ®Google Scholar
• Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol. Ther.21(4), 363–371 (2005).
   PubMed Web of Science ®Google Scholar
• Löfberg R, Rutgeerts P, Malchow H et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease. A placebo controlled one year study. Gut39(1), 82–86 (1996).
   PubMed Web of Science ®Google Scholar
• Cortot A, Colombel JF, Rutgeerts P et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut48(2), 186–190 (2001).
   PubMed Web of Science ®Google Scholar
• Gross V, Andus T, Ecker KW et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease. The Budesonide Study Group. Gut42(4), 493–496 (1998).
   PubMed Web of Science ®Google Scholar
• de Jong DJ, Bac DJ, Tan G et al. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn’s disease in remission. Neth. J. Med.65(9), 339–345 (2007).
   PubMed Web of Science ®Google Scholar
• Schoon EJ, Bollani S, Mills PR et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin. Gastroenterol. Hepatol.3(2), 113–121 (2005).
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Petraki K, Sfakianakis M et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn’s disease. Clin. Gastroenterol. Hepatol.1(2), 122–128 (2003).
   PubMed Web of Science ®Google Scholar
• Hellers G, Cortot A, Jewell D et al. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. The IOIBD Budesonide Study Group. Gastroenterology116(2), 294–300 (1999).
   PubMed Web of Science ®Google Scholar
• Ewe K, Böttger T, Buhr HJ, Ecker KW, Otto HF. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur. J. Gastroenterol. Hepatol.11(3), 277–282 (1999).
   PubMed Web of Science ®Google Scholar
• Schölmerich J. Review article: systemic and topical steroids in inflammatory bowel disease. Aliment Pharmacol. Ther.20(Suppl. 4), 66–74 (2004).
   PubMedGoogle Scholar
• Gross V, Bar-Meir S, Lavy A et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol. Ther.23(2), 303–312 (2006).
   PubMed Web of Science ®Google Scholar
• Hartmann F, Stein J; BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol. Ther.32(3), 368–376 (2010).
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut40(6), 775–781 (1997).
   PubMed Web of Science ®Google Scholar
• Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. (10), CD007698 (2010).
   Google Scholar
• D’Haens G, Kovács A, Vergauwe P et al. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J. Crohn’s Colitis4(2), 153–160 (2010).
   Google Scholar
• Gross V, Bunganic I, Mikhailova TL et al. Efficacy and tolerability of a once daily treatment with budesonide capsules versus mesalamine granules for the treatment of active ulcerative colitis: a randomized, double-blind, double-dummy, multicenter study. Gastroenterology136(5 Suppl. 1), A15 (2009).
   Google Scholar
• Lindgren S, Lofberg R, Bergholm L et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand. J. Gastroenterol.37(6), 705–710 (2002).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Löfberg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N. Engl. J. Med.331(13), 842–845 (1994).
   PubMed Web of Science ®Google Scholar
• Bar-Meir S, Chowers Y, Lavy A et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology115(4), 835–840 (1998).
   PubMed Web of Science ®Google Scholar
• Levine A, Weizman Z, Broide E et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr.36(2), 248–252 (2003).
   PubMed Web of Science ®Google Scholar
• Escher JC; European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur. J. Gastroenterol. Hepatol.16(1), 47–54 (2004).
   PubMed Web of Science ®Google Scholar
• Tursi A, Giorgetti GM, Brandimarte G, Elisei W, Aiello F. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn’s disease: an open-label, budesonide-controlled, randomized study. Med. Sci. Monit.12(6), PI29–PI32 (2006).
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N. Engl. J. Med.331(13), 836–841 (1994).
   PubMed Web of Science ®Google Scholar
• Tremaine WJ, Hanauer SB, Katz S et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am. J. Gastroenterol.97(7), 1748–1754 (2002).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am. J. Gastroenterol.100(8), 1780–1787 (2005).
   PubMed Web of Science ®Google Scholar
• Berkelhammer C, Trabolsi M, Andrejic J, Yasmeen T. Severe adrenal insufficiency complicating budesonide therapy for Crohn’s disease. Inflamm. Bowel Dis.17(4), 1053–1054 (2010).
   Google Scholar
• Heeringa M, Zweers P, de Man RA, de Groot H. Drug points: anaphylactic-like reaction associated with oral budesonide. BMJ321(7266), 927 (2000).
   PubMed Web of Science ®Google Scholar
• Mangone M, Spagnolo A, Capurso G et al. Rhabdomyolysis due to severe hypokaliemia in a Crohn’s disease patient after budesonide treatment. Dig. Liver Dis.39(8), 776–779 (2007).
   PubMedGoogle Scholar
• Malik M, Tobin A-M, Shanahan F, O’Morain C, Kirby B, Bourke J. Steroid allergy in patients with inflammatory bowel disease. Br. J. Dermatol.157(5), 967–969 (2007).
   PubMedGoogle Scholar
• Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis. Aliment Pharmacol. Ther.29(6), 643–653 (2009).
   PubMed Web of Science ®Google Scholar
• Kundhal P, Zachos M, Holmes JL, Griffiths AM. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J. Pediatr. Gastroenterol. Nutr.33(1), 75–80 (2001).
   PubMed Web of Science ®Google Scholar
• Beaulieu DB, Ananthakrishnan AN, Issa M et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm. Bowel Dis.15(1), 25–28 (2009).
   PubMed Web of Science ®Google Scholar
• Entecort®, package insert. AstraZeneca AB SS, Södertälje, Sweden.
   Google Scholar